International Stem Cell CORP — fact timeline

International Stem Cell CORP shareholders approved Election of four directors to hold office until the 2027 Annual Meeting at the 2026-06-11 meeting.

“Proposal 1: Election of four directors to hold office until the 2027 Annual Meeting: A. Directors elected by holders of Series D Preferred Stock: FOR WITHHELD Andrey Semechkin 2,457,143 0 Russell Kern 2,457,143 0 B. Directors elected by holders of all shares of stock (including shares of preferred stock voting on an as-converted basis): FOR WITHHELD Donald A. Wright 9,288,444 30,590 Paul V. Maier 9,288,500 30,534 Broker Non-Votes: none All of the foregoing candidates were elected.”

International Stem Cell CORP amended loan of $2,500,000 with Dr. Andrey Semechkin at 5.5% per annum maturing September 15, 2026.

“On September 15, 2025, International Stem Cell Corporation (the “Company”) and Dr. Andrey Semechkin agreed to extend (until September 15, 2026) the maturity date of the loan (in the principal amount of $2,500,000) from Dr. Semechkin to the Company that had been reflected in a promissory note dated September 15, 2024 (the “Original Note”), and which would have been due on September 15, 2024.”

International Stem Cell CORP incurred loan of $2,900,000 with Dr. Andrey Semechkin at four and a half percent (4.5%) per annum maturing September 15, 2024.

“On September 15, 2023, International Stem Cell Corporation (the "Company") and Dr. Andrey Semechkin agreed to extend (until September 15, 2024) the maturity date of the loan (in the principal amount of $2,900,000) from Dr. Semechkin to the Company that had been reflected in a promissory note dated March 15, 2023 (the "Original Note"), and which would have been due on September 15, 2023.”

International Stem Cell CORP entered into Note with Dr. Andrey Semechkin valued at principal amount of $2,900,000 (effective 2023-09-15).

“On September 15, 2023, International Stem Cell Corporation (the “Company”) and Dr. Andrey Semechkin agreed to extend (until September 15, 2024) the maturity date of the loan (in the principal amount of $2,900,000) from Dr. Semechkin to the Company that had been reflected in a promissory note dated March 15, 2023 (the “Original Note”), and which would have been due on September 15, 2023. In exchange for the Original Note, the Company issued to Dr. Semechkin an unsecured, non-convertible promissory note in the principal amount of $2,900,000 (the “Note”) with the extended maturity date.”

International Stem Cell CORP shareholders approved Election of four directors to hold office until the 2024 Annual Meeting at the 2023-06-14 meeting.

“International Stem Cell Corporation (the "Company") held its Annual Meeting of Stockholders on June 14, 2023. The stockholders considered two proposals, which are described in more detail in the Company's definitive proxy statement dated April 28, 2023. Proposal 1: Election of four directors to hold office until the 2024 Annual Meeting: A. Directors elected by holders of Series D Preferred Stock: FOR WITHHELD Andrey Semechkin 2,457,143 0 Russell Kern 2,457,143 0 B. Directors elected by holders of all shares of stock (including shares of preferred stock voting on an as-converted basis): FOR WITHHELD Donald A. Wright 7,833,624 44,091 Paul V. Maier 7,834,844 42,871 Broker Non-Votes: none All of the foregoing candidates were elected.”

International Stem Cell CORP incurred loan of $2,900,000 with Dr. Andrey Semechkin at four and a half percent (4.5%) per annum maturing September 15, 2023.

“extend (until September 15, 2023) the maturity date of the loan (in the principal amount of $2,900,000) from Dr. Semechkin to the Company that had been reflected in a promissory note dated September 15, 2022 (the “Original Note”), and which would have been due on March 15, 2023. In exchange for the Original Note, the Company issued to Dr. Semechkin an unsecured, non-convertible promissory note in the principal amount of $2,900,000 (the “Note”) with the extended maturity date.”

Russell Kern was appointed as principal financial officer at International Stem Cell CORP.

“On April 25, 2022, International Stem Cell Corporation, a Delaware corporation (the “Company”) appointed Dr. Russell Kern as its principal financial officer effective immediately.”

Sophia Garnette resigned as Principal Financial Officer and VP of Legal Affairs and Operations at International Stem Cell CORP.

“On February 1, 2022, Sophia Garnette, Principal Financial Officer and VP of Legal Affairs and Operations of International Stem Cell Corporation (the "Company"), submitted her resignation, to be effective on April 1, 2022.”